{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:04:31Z","timestamp":1775815471905,"version":"3.50.1"},"reference-count":48,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Brotman Baty Institute for Precision Medicine"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,2]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our study was designed to assess whether paired normal-tumour testing increased access to targeted therapy, clinical trials and influenced cancer screening recommendations given to patients and their families.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Prospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Academic cancer centre in the Pacific Northwest region of the USA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Patients newly diagnosed between 01 January 2021 and 31 December 2022 with cancers of the oesophagus, gastro-oesophageal junction and stomach (CEGEJS) were included. All other cancer diagnoses such as head and neck, duodenal and lower gastrointestinal tract cancers were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Paired germline and tumour genetic test within 90 days of new patient visit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary outcome measures<\/jats:title>\n                  <jats:p>Number of targeted therapies received (or not) when eligible, follow-up treatment data and number of inherited predispositions to cancers identified. No secondary outcome measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 42 patients, 32 (76.2%) were eligible for at least one targeted therapy. 19 patients received immunotherapy, when 16 had a biomarker predicting immunotherapy benefit, and benefit of immunotherapy was unclear for 3. Another 11 did not have this biomarker, and 6 of them received immunotherapy. Six pathogenic variants were identified in four high-risk genes. By 01 January 2024, 18 patients (42.9%) had died of complications of cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>More than 75% of patients who received tumour testing were eligible for a targeted therapy regardless of their stage at diagnosis, emphasising the need to expand access to testing with staging workup to improve survival outcomes. Six families received personalised screening recommendations, thanks to this study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-091745","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T02:15:38Z","timestamp":1748312138000},"page":"e091745","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Does paired genetic testing improve targeted therapy choices and screening recommendations for patients with upper gastrointestinal cancers and their families? A prospective cohort of 42 patients"],"prefix":"10.1136","volume":"15","author":[{"given":"Kevin","family":"Tatunay","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-9856","authenticated-orcid":false,"given":"Stacey","family":"Cohen","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"},{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine V","family":"Naylor","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia L","family":"Handford","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Jacobson","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Shankaran","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"},{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brant","family":"Oelschlager","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M","family":"Grady","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"},{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Sjoding","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everett","family":"Lally","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Facchini","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy Y","family":"Laurino","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Pritchard","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Q","family":"Konnick","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5735-1819","authenticated-orcid":false,"given":"Marianne E","family":"Dubard-Gault","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"},{"name":"Oncology, Providence Swedish Caner Institute, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2025101813015460000_15.5.e091745.1","unstructured":"SEER . Cancer of the esophagus - cancer stat facts. n.d. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/esoph.html"},{"key":"2025101813015460000_15.5.e091745.2","unstructured":"SEER . Cancer of the stomach - cancer stat facts. n.d. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html"},{"key":"2025101813015460000_15.5.e091745.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"2025101813015460000_15.5.e091745.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2011.12.008"},{"key":"2025101813015460000_15.5.e091745.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445"},{"key":"2025101813015460000_15.5.e091745.6","unstructured":"Practice-changing keynote-177 results support first-line pembrolizumab monotherapy for MSI-H mCRC. Available: https:\/\/dailynews.ascopubs.org\/do\/10.1200\/ADN.20.200206\/full\/?cid=DM5445 [Accessed 31 May 2020]."},{"key":"2025101813015460000_15.5.e091745.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2025101813015460000_15.5.e091745.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"2025101813015460000_15.5.e091745.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025101813015460000_15.5.e091745.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1678"},{"key":"2025101813015460000_15.5.e091745.11","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic Implications of Germline Testing in Patients With Advanced Cancers","volume":"39","author":"Stadler","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025101813015460000_15.5.e091745.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"2025101813015460000_15.5.e091745.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02005-6","article-title":"PARP inhibitors in gastric cancer: beacon of hope","volume":"40","author":"Wang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2025101813015460000_15.5.e091745.14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2023.41.4_suppl.404","article-title":"A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer","volume":"41","author":"Kim","year":"2023","journal-title":"JCO"},{"key":"2025101813015460000_15.5.e091745.15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025101813015460000_15.5.e091745.16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cgh.2018.05.044","article-title":"Incidence Trends of Esophageal and Gastric Cancer Subtypes by Race, Ethnicity, and Age in the United States, 1997-2014","volume":"17","author":"Islami","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025101813015460000_15.5.e091745.17","unstructured":"National Comprehensive Cancer Network . Esophageal and esophagogastric junction cancer. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal.pdf [Accessed 14 Aug 2020]."},{"key":"2025101813015460000_15.5.e091745.18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamaoncol.2014.187","article-title":"Hereditary Gastric Cancer: An Update at 15 Years","volume":"1","author":"Ford","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025101813015460000_15.5.e091745.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1029"},{"key":"2025101813015460000_15.5.e091745.20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/2050640618817098","article-title":"Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett\u2019s esophagus","volume":"7","author":"Tofani","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"2025101813015460000_15.5.e091745.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"2025101813015460000_15.5.e091745.22","unstructured":"National Comprehensive Cancer Network . Gastric cancer. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf [Accessed 14 Aug 2020]."},{"key":"2025101813015460000_15.5.e091745.23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000362575","article-title":"Hereditary Factors in Esophageal Adenocarcinoma","volume":"1","author":"van Nistelrooij","year":"2014","journal-title":"Gastrointest Tumors"},{"key":"2025101813015460000_15.5.e091745.24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10689-017-0054-2","article-title":"Germline variant in MSX1 identified in a Dutch family with clustering of Barrett\u2019s esophagus and esophageal adenocarcinoma","volume":"17","author":"van Nistelrooij","year":"2018","journal-title":"Fam Cancer"},{"key":"2025101813015460000_15.5.e091745.25","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31821628b6"},{"key":"2025101813015460000_15.5.e091745.26","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.40374"},{"key":"2025101813015460000_15.5.e091745.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00283"},{"key":"2025101813015460000_15.5.e091745.28","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21609"},{"key":"2025101813015460000_15.5.e091745.29","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30328-0"},{"key":"2025101813015460000_15.5.e091745.30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn366"},{"key":"2025101813015460000_15.5.e091745.31","unstructured":"National Comprehensive Cancer Network . Gastric cancer and esophageal and esophagogastric junction cancer. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf [Accessed 14 Aug 2020]."},{"key":"2025101813015460000_15.5.e091745.32","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00720","article-title":"Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays","volume":"7","author":"Krumm","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2025101813015460000_15.5.e091745.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1802313"},{"key":"2025101813015460000_15.5.e091745.34","unstructured":"Broca cancer risk panel. n.d. Available: https:\/\/testguide.labmed.uw.edu\/view\/BROCA"},{"key":"2025101813015460000_15.5.e091745.35","unstructured":"UW Oncoplex cancer gene panel. n.d. Available: https:\/\/testguide.labmed.uw.edu\/view\/OPX"},{"key":"2025101813015460000_15.5.e091745.36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/jgc4.1459","article-title":"Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings","volume":"31","author":"Lin","year":"2022","journal-title":"J Genet Couns"},{"key":"2025101813015460000_15.5.e091745.37","doi-asserted-by":"publisher","DOI":"10.1111\/cge.14006"},{"key":"2025101813015460000_15.5.e091745.38","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.223677"},{"key":"2025101813015460000_15.5.e091745.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4836"},{"key":"2025101813015460000_15.5.e091745.40","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2023.13770","article-title":"Role of FBXW7 expression in gastric cancer: Meta\u2011analysis and bioinformatics analysis","volume":"25","author":"Sun","year":"2023","journal-title":"Oncol Lett"},{"key":"2025101813015460000_15.5.e091745.41","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-00999-9"},{"key":"2025101813015460000_15.5.e091745.42","doi-asserted-by":"crossref","first-page":"viii25","DOI":"10.1093\/annonc\/mdy269.081","article-title":"Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer","volume":"29","author":"Liu","year":"2018","journal-title":"Ann Oncol"},{"key":"2025101813015460000_15.5.e091745.43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002013"},{"key":"2025101813015460000_15.5.e091745.44","unstructured":"University of Wisconsin School of Medicine Public Health . 2015 area deprivation index v2.0. 2015. Available: https:\/\/www.neighborhoodatlas.medicine.wisc.edu\/"},{"key":"2025101813015460000_15.5.e091745.45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/cge.14276","article-title":"Evaluation of out-of-pocket pay genetic testing in a publicly funded healthcare system","volume":"103","author":"Grant","year":"2023","journal-title":"Clin Genet"},{"key":"2025101813015460000_15.5.e091745.46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060838","article-title":"Hereditary Predispositions to Myelodysplastic Syndrome","volume":"17","author":"Bannon","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2025101813015460000_15.5.e091745.47","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1007\/s10620-022-07387-x","article-title":"Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study","volume":"67","author":"Uson","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2025101813015460000_15.5.e091745.48","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu120"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-091745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:02:06Z","timestamp":1760817726000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-091745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,26]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2024-091745"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-091745","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}